Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.

A novel strategy incorporating the use of prostate cancer patient-derived xenograft models and sequence data analysis has led to the discovery of a stromal gene signature that can serve as a new independent biomarker for risk stratification for patients with primary prostate cancer.